

Jes s Gonz lez-Bosquet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3391299/publications.pdf>

Version: 2024-02-01

76
papers

3,963
citations

218677

26
h-index

118850

62
g-index

76
all docs

76
docs citations

76
times ranked

6688
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparity of ovarian cancer survival between urban and rural settings. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 540-546.	2.5	7
2	Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1079.	4.1	7
3	Creation and validation of models to predict response to primary treatment in serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 5957.	3.3	13
4	Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome. <i>Cancers</i> , 2021, 13, 1109.	3.7	7
5	Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4791.	4.1	4
6	Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proof-of-concept study. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13469.	1.2	2
7	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 182-189.	1.4	6
8	A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemo-response in high-grade serous ovarian cancer. <i>Oncology Letters</i> , 2021, 22, 733.	1.8	3
9	The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 942.	3.8	3
10	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. <i>PLoS ONE</i> , 2021, 16, e0245664.	2.5	5
11	Foreword: New and Novel Treatments for Gynecologic Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 1-2.	1.1	0
12	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 92-108.	1.1	6
13	Gynecologic Oncology: Challenges of Minimally Invasive Surgery In a Field of Maximal Complexities. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 30-39.	1.1	5
14	Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 845-852.	2.5	29
15	An integrated prediction model of recurrence in endometrial endometrioid cancers. <i>Cancer Management and Research</i> , 2019, Volume 11, 5301-5315.	1.9	17
16	Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1192.	4.1	6
17	A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1205.	4.1	12
18	Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1175.	4.1	11

#	ARTICLE	IF	CITATIONS
19	Differential DNA methylation in high-grade serous ovarian cancer (HGSOc) is associated with tumor behavior. <i>Scientific Reports</i> , 2019, 9, 17996.	3.3	24
20	Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 260-266.	2.5	7
21	The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7205-7211.	2.0	8
22	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2017, 146, 247-253.	1.4	23
23	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 648-653.	1.4	21
24	Role of metadherin in estrogen-regulated gene expression. <i>International Journal of Molecular Medicine</i> , 2017, 40, 303-310.	4.0	3
25	Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18â€“Positive Cervical Cancers Is Associated With Tumor Histology. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 784-790.	2.5	9
26	p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. <i>International Journal of Oncology</i> , 2017, 50, 1721-1728.	3.3	12
27	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. <i>Gynecologic Oncology</i> , 2016, 142, 150-157.	1.4	6
28	Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. <i>Oncology Letters</i> , 2016, 11, 323-329.	1.8	8
29	Prediction of chemo-response in serous ovarian cancer. <i>Molecular Cancer</i> , 2016, 15, 66.	19.2	33
30	Differentially expressed genes in preimplantation human embryos: potential candidate genes for blastocyst formation and implantation. <i>Journal of Assisted Reproduction and Genetics</i> , 2016, 33, 1017-1025.	2.5	15
31	Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2016, 7, 41-4.	0.4	2
32	Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1000-1009.	2.5	6
33	Clinicopathological predictors of chemoresponsiveness in epithelial ovarian cancer: a preliminary institutional study. <i>Proceedings in Obstetrics and Gynecology</i> , 2015, 5, 1-13.	0.1	0
34	Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data. <i>Cancer Research</i> , 2014, 74, 3902-3912.	0.9	34
35	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. <i>Molecular Cancer</i> , 2014, 13, 129.	19.2	372
36	Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. <i>Oncology Reports</i> , 2014, 31, 376-383.	2.6	18

#	ARTICLE	IF	CITATIONS
37	Development of an Intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation. <i>Current Pharmaceutical Design</i> , 2014, 20, 1664-1673.	1.9	0
38	Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 208, 501.e1-501.e7.	1.3	14
39	Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 576.e1-576.e16.	1.3	10
40	A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2013, 130, 19-24.	1.4	28
41	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. <i>Oncology Reports</i> , 2013, 29, 2011-2018.	2.6	23
42	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
43	Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 960-967.	2.5	17
44	BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. <i>Journal of Gynecologic Oncology</i> , 2012, 23, 35.	2.2	22
45	The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. <i>International Journal of Oncology</i> , 2012, 41, 179-88.	3.3	7
46	The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. <i>Gynecologic Oncology</i> , 2012, 124, 119-124.	1.4	20
47	Fine mapping of 14q24.1 breast cancer susceptibility locus. <i>Human Genetics</i> , 2012, 131, 479-490.	3.8	5
48	Comparison of gene expression patterns between avian and human ovarian cancers. <i>Gynecologic Oncology</i> , 2011, 120, 256-264.	1.4	18
49	BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. <i>Clinical Cancer Research</i> , 2011, 17, 6356-6366.	7.0	97
50	Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. <i>Human Molecular Genetics</i> , 2011, 20, 2869-2878.	2.9	43
51	<i>LIN28B</i> Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 3896-3903.	0.9	75
52	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1793-1797.	2.5	19
53	Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers. <i>PLoS ONE</i> , 2011, 6, e14522.	2.5	52
54	The Impact of Multimodal Therapy on Survival for Uterine Carcinosarcomas. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 313-314.	0.4	1

#	ARTICLE	IF	CITATIONS
55	The impact of multi-modal therapy on survival for uterine carcinosarcomas. <i>Gynecologic Oncology</i> , 2010, 116, 419-423.	1.4	114
56	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2106-2109.	2.5	24
57	Genome-wide association studies in cancer—current and future directions. <i>Carcinogenesis</i> , 2010, 31, 111-120.	2.8	100
58	Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. <i>Carcinogenesis</i> , 2010, 31, 827-833.	2.8	42
59	Fine mapping and functional analysis of a common variant in <i>MSMB</i> on chromosome 10q11.2 associated with prostate cancer susceptibility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7933-7938.	7.1	96
60	Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 3-11.	1.4	57
61	Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the <i>MSMB</i> gene associated with prostate cancer. <i>Human Genetics</i> , 2009, 126, 743-750.	3.8	21
62	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (<i>RAD51L1</i>). <i>Nature Genetics</i> , 2009, 41, 579-584.	21.4	487
63	Identification of a new prostate cancer susceptibility locus on chromosome 8q24. <i>Nature Genetics</i> , 2009, 41, 1055-1057.	21.4	218
64	Principles of analysis of germline genetics. , 2009, , 13-35.		0
65	Multiple loci identified in a genome-wide association study of prostate cancer. <i>Nature Genetics</i> , 2008, 40, 310-315.	21.4	871
66	Current Issues in the Management of Endometrial Cancer. <i>Mayo Clinic Proceedings</i> , 2008, 83, 97-112.	3.0	128
67	Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2007, 105, 742-746.	1.4	66
68	Hepatic resection for metachronous metastases from ovarian carcinoma. <i>Hpb</i> , 2006, 8, 93-96.	0.3	8
69	Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2005, 97, 828-833.	1.4	114
70	Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. <i>Gynecologic Oncology</i> , 2005, 99, 135-141.	1.4	63
71	Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. <i>Gynecologic Oncology</i> , 2003, 91, 518-525.	1.4	43
72	Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 419-424.	0.8	41

#	ARTICLE	IF	CITATIONS
73	Small bowel obstruction associated with post-hysterectomy vaginal vault prolapse. <i>Obstetrics and Gynecology</i> , 2003, 102, 524-526.	2.4	8
74	Squamous Cell Carcinoma of the Vulva Stage IA: Long-Term Results. <i>Gynecologic Oncology</i> , 2000, 76, 24-27.	1.4	71
75	Primary Squamous Cell Cancer of the Vulva: Radical versus Modified Radical Vulvar Surgery. <i>Gynecologic Oncology</i> , 1998, 71, 116-121.	1.4	68
76	Merkel Cell Carcinoma of the Vulva. <i>Gynecologic Oncology</i> , 1997, 64, 526-532.	1.4	30